Edition:
United States

People: Johnson & Johnson (JNJ)

JNJ on New York Consolidated

133.01USD
24 Jul 2017
Change (% chg)

$-2.30 (-1.70%)
Prev Close
$135.31
Open
$134.99
Day's High
$135.16
Day's Low
$132.85
Volume
8,306,444
Avg. Vol
5,897,993
52-wk High
$137.08
52-wk Low
$109.32

Stoffels, Paulus 

Dr. Paulus A. Stoffels is Executive Vice President, Chief Scientific Officer of Johnson & Johnson. Dr. P. Stoffels joined the Company in 2002 with the acquisition of Tibotec Virco NV, where he was Chief Executive Officer of Virco NV and Chairman of Tibotec NV. In 2005, he was appointed Company Group Chairman, Global Virology. In 2006, he assumed the role of Company Group Chairman, Pharmaceuticals, with responsibility for worldwide research and development for the Central Nervous System and Internal Medicine Franchises. Dr. Stoffels was appointed Global Head, Research & Development, Pharmaceuticals in 2009, and in 2011, became Worldwide Chairman, Pharmaceuticals, with responsibility for the Company's therapeutic pipeline through global research and development and strategic business development. In 2012, Dr. Stoffels was also appointed Chief Scientific Officer, with responsibility for enterprise-wide innovation and product safety, and a member of the Executive Committee.

Basic Compensation

Total Annual Compensation, USD 3,569,460
Restricted Stock Awards, USD 4,383,450
Long-Term Incentive Plans, USD --
All Other, USD 4,772,560
Fiscal Year Total, USD 12,725,500

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised 125,000 3,722,500.00
Name Fiscal Year Total

Alex Gorsky

26,871,700

Dominic Caruso

11,304,800

Peter Fasolo

3,621,280

Paulus Stoffels

12,725,500

Michael Ullmann

5,676,350

Joaquin Duato

10,104,500
As Of  31 Dec 2016